ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) reached 16% versus a 1-year low price of $0.25. The stock was last seen -6.48% lower, reaching at $0.29 on 12/05/2017. At recent session, the prices were hovering between $0.28 and $0.31. This company shares are 1624.14% off its target price of $5 and the current market capitalization stands at $6.86M. The recent change has given its price a -18.93% deficit over SMA 50 and -93.21% deficit over its 52-week high. The stock witnessed -17.24% declines, 6.62% gains and -74.34% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found IMUC’s volatility during a week at 9.75% and during a month it has been found around 8.17%.ImmunoCellular Therapeutics, Ltd. 13F Filings
At the end of 09/30/2017 reporting period, 9 institutional holders increased their position in ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) by some 793,850 shares, 4 decreased positions by 793 and 8 held positions by 257,799. That puts total institutional holdings at 1,052,442 shares, according to SEC filings. The stock grabbed 5 new institutional investments totaling 159,833 shares while 3 institutional investors sold out their entire positions totaling 176 shares.
Multiple company employees have indulged in significant insider trading. ImmunoCellular Therapeutics, Ltd. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President and CEO Gengos Andrew has acquired 250 shares of ImmunoCellular Therapeutics, Ltd. (IMUC) in trading session dated Nov. 30, 2015. These shares are worth $4,400 and were traded at $17.6 each. The SEC filing shows that Gringeri Anthony performed a purchase of 750 shares. The Senior VP Strategic Resources added these shares by way of transaction on Feb. 18, 2015. The company’s shares were assimilated at $24 per share worth to an investment of some $18,000 on account of Gringeri Anthony.
President and CEO, Gengos Andrew, purchased 1,033 common shares of ImmunoCellular Therapeutics, Ltd. (IMUC) in the open market. In a transaction dated Feb. 18, 2015, the shares were bought at an average price of $24, giving away a sum of $24,792. After this purchase, 1,958 common shares of IMUC are directly owned by the insider, with total stake valued at $568.
In the transaction dated Feb. 18, 2015, the great number of shares acquired came courtesy the VP of Finance; Fractor David added a total of 417 shares at an average price of $24, amounting to approximately $10,008. The insider now directly owns 1,042 shares worth $302.ImmunoCellular Therapeutics, Ltd. (IMUC) Analyst Guide
Several analysts have released their opinion on ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC), with 0 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 3 average brokerage recommendation.